A Phase 2 interventional study of Glyceryl trinitrate and MED Placebo in Erectile Dysfunction, sponsored by Futura Medical Developments Ltd.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.
Sponsored by Futura Medical Developments Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Erectile Dysfunction with a site in United Kingdom — 3 open to participants now, 4 under way, none of them phase 3. Erectile Dysfunction · United Kingdom.
Among the 25 studies in Erectile Dysfunction with a site in United Kingdom, this one is the 13th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2015, is one of 4 in phase 2, and was the 18th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →3 of the 25 studies in Erectile Dysfunction with a site in United Kingdom are open now. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 18–79 · Men only
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 40–65 · Men only
University College, London · Sites in United Kingdom
Ages up to 90 · Men only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 232 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 260 across the 23 interventional studies, 558 across the 2 observational. Of the 20 that completed or were terminated, 6 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
Futura Medical Developments Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Futura Medical Developments Ltd. has 4 studies filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
1 of the studies in Erectile Dysfunction with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07597798University College, LondonEVERiST: Impact of Image Detected Accessory Pudendal Artery on Erection Recovery After Nerve Sparing Prostatectomy | 2027-07-15 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Erectile Dysfunction with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the efficacy and safety of MED2005, a topically applied glyceryl trinitrate (GTN) gel administered to the penis of male subjects self-diagnosed with erectile dysfunction (ED) immediately before sexual intercourse.
This randomised, double-blind, placebo-controlled cross-over study is designed to evaluate the efficacy and safety of MED2005, a topically applied glyceryl trinitrate (GTN) gel administered to the penis of male subjects immediately before sexual intercourse. Subjects will be male aged between 18 and 70 years of age self-diagnosed with ED. Treatment requires the topical application of a pea sized volume (approximately 300 mg) of a 0.2% (w/w) gel to deliver a dose of 0.6 mg GTN to the glans of the penis. A total of 192 eligible subjects are planned to be enrolled into the study. Subjects will be screened for eligibility during the screening period (Day -45 to Day -2), provide a history of their ED treatments and those deemed eligible and who have a female consenting partner will participate in a run-in-period and two treatment periods (treatment period 1 and 2). The International Index for Erectile Function (IIEF) question 1 -5 and 15 will be used to determine pre-screening eligibility for the subject online. A score of 25 or less will be acceptable for inclusion to the run-in-period. Screening (visit 1) will be conducted over 1 day or may be divided into more than 1 day if wash-out of prior medications is needed. The screening period is applicable for visit 1 Informed consent will be signed by both partners before a couple can be admitted to the study. There will also be a subject and partner training requirement to ensure that the product is applied in an appropriate manner. After refraining from using other ED treatments for at least a period of a week, in the run-in-period (visit 2), subjects and their female partners will make at least 4 intercourse attempts (with a minimum of 1 attempt per week) during a 4 week (± 1 week) period. The subjects and their partners will be asked to complete questionnaires online to record their experiences after each sexual intercourse attempt and at the end of the run-in period. Subjects who cannot comply with the minimum number of sexual attempts verified by completed Sexual Event Profile (SEP) or exceed 25 on the IIEF question 1 -5 and 15 will be excluded from the study. Scores generated from the run-in period will be used as an established baseline in the planned analyses. The run-in period will be completed prior to randomisation and dosing.
In treatment period 1 (visit 3 and visit 4), subjects will be allocated to receive either placebo or MED2005 (0.6 mg GTN) according to a pre-defined randomisation schedule. After refraining from using other ED treatments for at least a period of a week, subjects and their female partner will be trained in the application of the test article and asked to apply the test article immediately prior to sexual intercourse, and to make at least 4 intercourse attempts during a 4 week (± 1 week) period. The subjects and their partners will be asked to complete questionnaires online to record their experiences after each sexual intercourse attempt, and again at the end of each treatment period. Subjects will be asked to return to the Clinical Pharmacology Unit (CPU) after 4 weeks' (± 1 week) to return used and unused test article from the first treatment period, to enable the clinical staff to check compliance and to assess their health status, including assessment of any Adverse Event (AE). At the end of treatment period 1 (visit 4), tubes will be weighed to ensure subject compliance.
Following a 1 week treatment-free cross-over period, the subjects will enter into treatment period 2.
In treatment period 2 (visit 5 and visit 6), subjects will be issued with the alternative test article, either placebo or MED2005 (0.6 mg GTN) according to the pre-defined randomisation code. Training on the application of the test article will be reinforced / repeated and the subject or their female partner will be asked to apply the test article immediately prior to sexual intercourse on at least 4 separate occasions during a 4-week period. After each intercourse attempt the subjects and their partners will be asked to complete questionnaires online to record their experiences after each sexual intercourse attempt, and again at the end of each treatment period.. Subjects will be asked to return to the CPU after 4 weeks' (± 1 week) time to return used and unused test article from the second treatment period, to enable the clinical staff to check compliance and to assess their health status, including assessment of any AEs. At the end of treatment period 2 (visit 6), tubes will be weighed to ensure subject compliance.
Subjects and their female partners will be followed up at 7 day's ± 2 days (visit 7) after the outpatient visit on week 4 of treatment period 2, as necessary, to follow up any on-going AEs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Both partners must agree to use one of the acceptable methods of listed below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
Drug: Glyceryl trinitrate · Drug: MED Placebo
Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
Drug: Glyceryl trinitrate · Drug: MED Placebo
At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
Also known as: MED2005
At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
Also known as: MED2005 Vehicle
Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF)
Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of the treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-30, a lower score is regarded as more severe.
Time frame: 4 Weeks
Orgasmic Function Domain Score of the International Index of Erectile (IIEF)
Orgasmic function domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-10, a lower score is regarded as having a worse outcome.
Time frame: 4 Weeks
Sexual Desire Domain Score of the International Index of Erectile Function (IIEF)
Sexual desire domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome.
Time frame: 4 Weeks
Intercourse Satisfaction Domain Score of the International Index of Erectile Function (IIEF)
Intercourse satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 0-15, a lower score is regarded as having a worse outcome.
Time frame: 4 Weeks
Overall Satisfaction Domain Score of the International Index of Erectile Function (IIEF)
Overall satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome.
Time frame: 4 weeks
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 1
SEP Question 1: "Were you able to achieve at least some erection (some enlargement of the penis)?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
Time frame: 4 Weeks
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 2
SEP Question 2: "Were you able to insert your penis into your partner's vagina?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
Time frame: 4 Weeks
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 3
SEP Question 3: "Did your erection last long enough for you to have successful intercourse?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
Time frame: 4 Weeks
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 4
SEP Question 4: "Were you satisfied with the hardness of your erection?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
Time frame: 4 Weeks
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 5
SEP Question 5: "Were you satisfied overall with this sexual experience?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
Time frame: 4 Weeks
Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1
GAQ Question 1: "Has the treatment you have been taking improved your erectile function?". Answered yes/no after each treatment period of 4 weeks (+/- 1 week).
Time frame: 4 Weeks
Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2
GAQ Question 2: "Has the treatment improved your ability to engage in sexual activity?". Answered yes/no after each treatment period of 4 weeks (+/- 1 week).
Time frame: 4 Weeks
| Milestone | MED Placebo Then MED2005 | MED2005 Then MED Placebo |
|---|---|---|
| Started | 114 | 118 |
| Completed | 114 | 118 |
| Not completed | 0 | 0 |
| Milestone | MED Placebo Then MED2005 | MED2005 Then MED Placebo |
|---|---|---|
| Started | 114 | 118 |
| Completed | 112 | 116 |
| Not completed | 2 | 2 |
| Milestone | MED Placebo Then MED2005 | MED2005 Then MED Placebo |
|---|---|---|
| Started | 112 | 116 |
| Completed | 112 | 113 |
| Not completed | 0 | 3 |
Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of the treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-30, a lower score is regarded as more severe.
| score on a scale | MED Placebo | MED2005 |
|---|---|---|
| Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF) | 18.5 ± 6.7 | 19.6 ± 7.5 |
Orgasmic function domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-10, a lower score is regarded as having a worse outcome.
| score on a scale | MED Placebo | MED2005 |
|---|---|---|
| Orgasmic Function Domain Score of the International Index of Erectile (IIEF) | 6.6 ± 2.6 | 7.0 ± 2.8 |
Sexual desire domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome.
| score on a scale | MED Placebo | MED2005 |
|---|---|---|
| Sexual Desire Domain Score of the International Index of Erectile Function (IIEF) | 7.1 ± 1.8 | 7.5 ± 1.8 |
Intercourse satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 0-15, a lower score is regarded as having a worse outcome.
| score on a scale | MED Placebo | MED2005 |
|---|---|---|
| Intercourse Satisfaction Domain Score of the International Index of Erectile Function (IIEF) | 8.6 ± 2.8 | 9.0 ± 2.8 |
Overall satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome.
| score on a scale | MED Placebo | MED2005 |
|---|---|---|
| Overall Satisfaction Domain Score of the International Index of Erectile Function (IIEF) | 6.6 ± 2.2 | 7.1 ± 2.3 |
SEP Question 1: "Were you able to achieve at least some erection (some enlargement of the penis)?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
| percentage of yes responses | MED Placebo | MED2005 |
|---|---|---|
| Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 1 | 86.93 ± 26.22 | 87.24 ± 26.47 |
SEP Question 2: "Were you able to insert your penis into your partner's vagina?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
| percentage of yes responses | MED Placebo | MED2005 |
|---|---|---|
| Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 2 | 75.37 ± 34.91 | 75.53 ± 36.49 |
SEP Question 3: "Did your erection last long enough for you to have successful intercourse?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
| percentage of yes responses | MED Placebo | MED2005 |
|---|---|---|
| Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 3 | 52.64 ± 38.81 | 57.32 ± 39.40 |
SEP Question 4: "Were you satisfied with the hardness of your erection?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
| percentage of yes responses | MED Placebo | MED2005 |
|---|---|---|
| Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 4 | 28.97 ± 33.12 | 42.91 ± 41.0 |
SEP Question 5: "Were you satisfied overall with this sexual experience?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.
| percentage of yes responses | MED Placebo | MED2005 |
|---|---|---|
| Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 5 | 36.88 ± 36.98 | 48.23 ± 40.87 |
GAQ Question 1: "Has the treatment you have been taking improved your erectile function?". Answered yes/no after each treatment period of 4 weeks (+/- 1 week).
| Participants | MED Placebo | MED2005 |
|---|---|---|
| Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1 | 56 | 94 |
GAQ Question 2: "Has the treatment improved your ability to engage in sexual activity?". Answered yes/no after each treatment period of 4 weeks (+/- 1 week).
| Participants | MED Placebo | MED2005 |
|---|---|---|
| Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2 | 54 | 85 |
Collected over 4 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MED Placebo | 0/227 (0%) | 0/227 (0%) | 15/227 (6.6%) |
| MED2005 | 0/229 (0%) | 0/229 (0%) | 28/229 (12.2%) |
| Event | MED Placebo | MED2005 |
|---|---|---|
| HeadacheNervous system disorders | 7/227 | 18/229 |
| NasopharyngitisInfections and infestations | 11/227 | 13/229 |
Safety Set. A total of 231 subjects made use of the medication at least once and were included in the safety set.
| Age, Continuous(years) | MED Placebo Then MED2005 | MED2005 Then MED Placebo | Total |
|---|---|---|---|
| Mean | 42.7 ± 13.7 | 43.3 ± 14.7 | 43.0 ± 14.2 |
| Sex: Female, Male(Participants) | MED Placebo Then MED2005 | MED2005 Then MED Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 114 | 117 | 231 |
| Race/Ethnicity, Customized(Participants) | MED Placebo Then MED2005 | MED2005 Then MED Placebo | Total |
|---|---|---|---|
| Asian | 5 | 4 | 9 |
| Black or African American | 7 | 10 | 17 |
| White | 97 | 97 | 194 |
| Other | 5 | 6 | 11 |
| Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF)(score on a scale) | MED Placebo Then MED2005 | MED2005 Then MED Placebo | Total |
|---|---|---|---|
| Mean | 17.1 ± 5.9 | 17.1 ± 5.5 | 17.1 ± 5.7 |
Ran from May 2015 to primary completion in Jul 2016, 14 months.
Results were first posted in Jan 2020, 3 years 5 months after primary completion.
Of 24 phase 2 interventional studies under Erectile Dysfunction, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitroglycerin
Futura Medical Developments Ltd.